PRAME-Binding TCR CDR Engineering for Safer Tumor Targeting

The patent applies local quality by making specific modifications only to the CDR regions (complementarity determining regions) of the TCR while keeping the framework regions unchanged. This allows targeted enhancement of antigen-binding affinity and specificity in the local binding interface without altering the overall TCR structure, thereby improving tumor recognition while maintaining safety through precise local optimization rather than global changes

The patent employs parameter changes by systematically varying amino acid sequences in the CDR regions to optimize binding parameters. Through iterative engineering of CDR sequences, the patent achieves enhanced affinity for cancer self-antigens while carefully controlling the balance between tumor recognition and cross-reactivity, demonstrating parameter optimization to resolve the contradiction between reliability and harmful effects

The patent applies preliminary action by conducting extensive in vitro characterization and affinity maturation of CDR variants before in vivo application. The systematic engineering and testing of CDR sequences in controlled environments allows prediction and mitigation of potential side effects before clinical use, thereby improving safety predictability while maintaining immune response effectiveness

The patent employs feedback mechanisms through iterative characterization of TCR variants, measuring binding affinities, specificity, and functional responses. This feedback loop allows optimization of CDR sequences to achieve the desired balance between productivity (immune effectiveness) and reliability (safety predictability) by learning from experimental results and refining the TCR design accordingly

The patent applies local quality by introducing stabilizing mutations specifically in the CDR regions and adjacent framework regions that are involved in antigen binding. These localized modifications enhance binding stability without causing widespread structural changes that would lead to aggregation, thereby maintaining production feasibility while improving antigen-binding stability

The patent employs parameter changes by systematically optimizing amino acid sequences in the CDR and framework regions to achieve the right balance between binding stability and solubility. Through controlled sequence engineering and characterization, the patent identifies mutations that improve stability parameters without crossing the threshold into aggregation-prone regimes, ensuring manufacturability